- Home
- HONE vs EOLS Comparison
HONE vs EOLS Comparison
Compare HONE & EOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HONE
- EOLS
- Stock Information
- Founded
- HONE 1917
- EOLS 2012
- Country
- HONE United States
- EOLS United States
- Employees
- HONE N/A
- EOLS N/A
- Industry
- HONE Major Banks
- EOLS Biotechnology: Pharmaceutical Preparations
- Sector
- HONE Finance
- EOLS Health Care
- Exchange
- HONE Nasdaq
- EOLS Nasdaq
- Market Cap
- HONE 547.7M
- EOLS 493.5M
- IPO Year
- HONE 2016
- EOLS 2018
- Fundamental
- Price
- HONE $13.18
- EOLS $6.54
- Analyst Decision
- HONE Buy
- EOLS Strong Buy
- Analyst Count
- HONE 3
- EOLS 5
- Target Price
- HONE $14.50
- EOLS $21.25
- AVG Volume (30 Days)
- HONE 198.2K
- EOLS 866.0K
- Earning Date
- HONE 10-23-2025
- EOLS 11-05-2025
- Dividend Yield
- HONE 2.76%
- EOLS N/A
- EPS Growth
- HONE 71.76
- EOLS N/A
- EPS
- HONE 0.65
- EOLS N/A
- Revenue
- HONE $164,819,000.00
- EOLS $277,941,000.00
- Revenue This Year
- HONE N/A
- EOLS $13.68
- Revenue Next Year
- HONE $14.24
- EOLS $27.96
- P/E Ratio
- HONE $20.08
- EOLS N/A
- Revenue Growth
- HONE N/A
- EOLS 17.15
- 52 Week Low
- HONE $8.89
- EOLS $5.71
- 52 Week High
- HONE $13.73
- EOLS $17.82
- Technical
- Relative Strength Index (RSI)
- HONE 66.28
- EOLS 33.26
- Support Level
- HONE $12.80
- EOLS $7.19
- Resistance Level
- HONE $13.18
- EOLS $7.58
- Average True Range (ATR)
- HONE 0.27
- EOLS 0.31
- MACD
- HONE 0.00
- EOLS -0.06
- Stochastic Oscillator
- HONE 74.09
- EOLS 2.39
About HONE HarborOne Bancorp Inc.
HarborOne Bancorp Inc is a bank holding company. The company is engaged in providing financial services like accepting deposits, lending loans, online and mobile banking, cash management, credit cards, money market accounts, and wealth management. The Company has two reportable segments: HarborOne Bank and HarborOne Mortgage. The bank provides financial services to individuals and businesses online and through its full-service branches located in Massachusetts and Rhode Island, one limited-service branch, and a commercial lending office in Boston, Massachusetts, and Providence, Rhode Island.
About EOLS Evolus Inc.
Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.